

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Tracy Ann Willson, et al.

Examiner: Unassigned

Serial No.: 09/868,813

Art Unit: Unassigned

Filing Date: June 21, 2001

Docket: 14730

For: SOCS-BOX CONTAINING PEPTIDES

Date: March 12, 2002

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, it is requested that the following reference(s), which is (are) also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. International Application WO 98/20023, published May 14, 1998;
2. International Application WO 98/14574, published April 9, 1998;
3. International Application WO 97/35978, published October 2, 1997;
4. International Application WO 99/03993, published January 28, 1999;
5. International Application WO 99/03994, published January 28, 1999;

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231 on March 12, 2002.

Dated: March 12, 2002


Michelle Mustafa

6. International Application WO 99/40946, published August 19, 1999;
7. Kamura, T., et al. (1998) "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 Repeat, and ankyrin repeat families", Genes Dev 12(24): 3872-3881;
8. Zhang, J. G., et al. (1999) "The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation", Proc Natl Acad Sci USA 96(5): 2071-2076;
9. Alexander, W.S., et al. (1999) "Suppressors of cytokine signaling (Socs): negative regulators of signal transduction", J. Leukoc Biol 66(4): 588-592;
10. Alexander, W.S., et al. (1999) "SOCS 1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine" Cell 98(5): 597-608; and
11. Bousquet, C., et al. (1999) "Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor" J. Clin Invest 104(9): 1277-1285.

The references were cited in a International Search Report dated February 11, 2000. Applicants are submitting copies of the above-cited references, together with a copy of the Search Report. The relevance of the above-identified references has been described in the Search Report.

Inasmuch as this Information Disclosure Statement is being submitted in accordance with the schedule set out in 37 C.F.R. § 1.97(b), no statement or fee is required

Respectfully submitted,




Frank S. DiGiglio
Registration No. 31,346

Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343
FSD/XZ:ab

Form PTO-1449
(REV. 7-80)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEAtty. Docket No.
14730Serial No.
09/868,813**LIST OF PRIOR ART
CITED BY APPLICANT**

(Use several sheets if necessary)

Applicant
Tracy Ann Willson, et al.Filing Date
June 21, 2001Group
Unassigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL*		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
	AA						
	AB						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AK	WO 98/20023	5/14/98	PCT				
	AL	WO 98/14574	4/9/98	PCT				
	AM	WO 97/35978	10/2/97	PCT				
	AN	WO 99/03993	1/28/99	PCT				
	AO	WO 99/03994	1/28/99	PCT				
	AP	WO 99/40946	8/19/99	PCT				

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AQ	Kamura, T., et al. (1998) "The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 Repeat, and ankyrin repeat families", <u>Genes Dev</u> 12(24): 3872-3881
AR	Zhang, J. G., et al. (1999) "The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation", <u>Proc Natl Acad Sci USA</u> 96(5):2071-2076
AS	Alexander, W.S., et al. (1999) "Suppressors of cytokine signaling (Socs): negative regulators of signal transduction", <u>J. Leukoc Biol</u> 66(4): 588-592
AT	Alexander, W.S., et al. (1999) "SOCS 1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine" <u>Cell</u> 98(5): 597-608
AU	Bousquet, C., et al. (1999) "Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor" <u>J. Clin Invest</u> 104(9): 1277-1285

EXAMINER

DATE CONSIDERED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
14730

In Re Application Of: Tracy Ann Willson, et al.

Serial No.
09/868,813

Filing Date
June 21, 2001

Examiner
Assigned

Group Art Unit
Unassigned

Title: SOCS-BOX CONTAINING PEPTIDES

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
14730

In Re Application Of: Tracy Ann Willson, et al.

Serial No.
09/868,813

Filing Date
June 21, 2001

Examiner
Unassigned

Group Art Unit
Unassigned

Title: SOCS-BOX CONTAINING PEPTIDES

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 19-1013/SSMP as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax No. _____) on _____ (Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on March 12, 2002 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

Signature of Person Mailing Correspondence

Michelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

Dated: March 12, 2002

Frank S. DiGiglio
Registration No. 31,346
Scully, Scott, Murphy & Presser
400 Garden City Plaza
Garden City, New York 11530
(516) 742-4343

CC: